Drug Discovery and Development

In an effort to increase the return on investment of research and development, pharmaceutical companies are constantly looking for ways to reduce costs. One way to do this is to incorporate technology and minimize human interaction. As a result, scientists will have more time to focus on the design and analysis of experiments. How will the Lab of the Future reflect these changes?

Every year cancer kills eight million people worldwide. By 2030, the number of annually diagnosed cases will exceed 21.7 million resulting in 13 million cancer deaths due to aging and population growth. Join the fight against cancer by embarking on a research mission to develop a personalized immunotherapy using augmented reality.

Frost & Sullivan, a business consulting firm involved in market research and analysis, conducted a thought leadership forum that brought together experts in the field of immuno-oncology. Follow their discussions about the current state of immunotherapies and the key challenges and future approaches to the targeted use of the immune system in cancer treatment.

Mock organs the size of a thumb drive are poised to revolutionize drug development and discovery. Dr. Dan Tagle at the NIH, the latest guest on Brilliant Science, specializes in divining new ways to innovate organs-on-chips, and he’s even sending them to space. Read more about this growing technology and its fascinating applications.

Frost & Sullivan, a business consulting firm involved in market research and analysis, conducted a thought leadership forum that brought together experts in the field of CNS biomarkers. Follow their discussions about technological advancements in the field and future implications of the current research and development.

The Brilliant Science podcasts will introduce you to some of the amazing science being done around the world. Join us every month to see what you can learn.

For the past 30 years, there has been one assumed culprit of Alzheimer’s disease (AD) — beta-amyloid. However, researchers have been unsuccessful in developing effective therapies targeting this protein. Understand the history of AD and beta-amyloid and see what other biomarkers are being investigated as potential therapeutic targets.

Ever wonder how football is linked to degenerative brain disease? Find out here. Also, learn about novel biomarkers for traumatic brain injury (TBI), the current state of TBI research, and promising new approaches for developing a robust diagnostic tool. Discover tests currently used to diagnose TBI and read about unusual techniques used to develop reliable biomarkers.

R-loops are being investigated as potential therapeutic targets for cancer. Find out what they are, how they form, how their formation is controlled by our cells, and, above all, their potential as therapeutic targets.

How well do you understand your microbiota? Dr. Allyson Byrd of Genentech, the fourth guest on Brilliant Science, is a bioinformatician focusing on parsing all the data our microbiomes have to offer. Read about the value of analyzing microbiota and how Dr. Byrd hopes to leverage the results.